A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers

Autor: Rim Hasan, Larry J. Prokop, Apostolos Tsapas, Anil Hingorani, Mohammad Hassan Murad, Gabriela Prutsky, Tarig Elraiyah, Juan Pablo Domecq, Paul L. Claus, Lawrence W. Steinkraus, Belal Firwana, Mohammed Nabhan
Rok vydání: 2015
Předmět:
Male
medicine.medical_specialty
medicine.medical_treatment
Vasodilator Agents
Tetrazoles
030209 endocrinology & metabolism
030204 cardiovascular system & hematology
Placebo
Pentoxifylline/therapeutic use
law.invention
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
medicine
Humans
purl.org/pe-repo/ocde/ford#3.02.04 [https]
Iloprost
Pentoxifylline
Aged
Diabetic Foot/drug therapy/therapy
Hyperbaric Oxygenation
business.industry
Odds ratio
Middle Aged
medicine.disease
Diabetic foot
Diabetic Foot
Surgery
Cilostazol
Diabetic foot ulcer
Treatment Outcome
Amputation
Meta-analysis
Tetrazoles/therapeutic use
Vasodilator Agents/therapeutic use
purl.org/pe-repo/ocde/ford#3.02.11 [https]
Female
Cardiology and Cardiovascular Medicine
business
Iloprost/therapeutic use
medicine.drug
Zdroj: Journal of vascular surgery. 63
ISSN: 1097-6809
Popis: BACKGROUND: Multiple adjunctive therapies have been proposed to accelerate wound healing in patients with diabetes and foot ulcers. The aim of this systematic review is to summarize the best available evidence supporting the use of hyperbaric oxygen therapy (HBOT), arterial pump devices, and pharmacologic agents (pentoxifylline, cilostazol, and iloprost) in this setting. METHODS: We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus through October 2011. Pairs of independent reviewers selected studies and extracted data. Predefined outcomes of interest were complete wound healing and amputation. RESULTS: We identified 18 interventional studies; of which 9 were randomized, enrolling 1526 patients. The risk of bias in the included studies was moderate. In multiple randomized trials, the addition of HBOT to conventional therapy (wound care and offloading) was associated with increased healing rate (Peto odds ratio, 14.25; 95% confidence interval, 7.08-28.68) and reduced major amputation rate (odds ratio, 0.30; 95% confidence interval, 0.10-0.89), compared with conventional therapy alone. In one small trial, arterial pump devices had a favorable effect on complete healing compared with HBOT and in another small trial compared with placebo devices. Neither iloprost nor pentoxifylline had a significant effect on amputation rate compared with conventional therapy. No comparative studies were identified for cilostazol in diabetic foot ulcers. CONCLUSIONS: There is low- to moderate-quality evidence supporting the use of HBOT as an adjunctive therapy to enhance diabetic foot ulcer healing and potentially prevent amputation. However, there are only sparse data regarding the efficacy of arterial pump devices and pharmacologic interventions.
Databáze: OpenAIRE